DAFTAR PUSTAKA

1. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009 July 1;125(1):229–34.

2. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 2015 Sept 20;33(27):3029–35.

3. Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M. Bone tumors in adolescents and young adults. Curr Treat Options Oncol. 2008 Feb;9(1):67–80.

4. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006 Sept 15;66(18):9054–64.

5. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 July 19;357(3):266–81.

6. Suzuki K, Takaharu K, Muto Y, Ichida K, Fukui T, Takayama Y, et al. XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI. Mol Clin Oncol. 2014 Sept;2(5):827–32.

7. Chen J, Sun M-X, Hua Y-Q, Cai Z-D. Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis. J Cancer Res Clin Oncol. 2014 July;140(7):1205–10.

8. Bacci G, Ferrari S, Sangiorgi L, Picci P, Casadei R, Orlandi M, et al. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother. 1994 June;6(3):204–10.

9. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.

10. Mulatsih S, Hanifah A, Oktasari R. The clinical evaluation and survival rate of pediatric sarcoma in Dr. Sardjito General Hospital, Yogyakarta, Indonesia. Indonesian Journal of Cancer. 2024 Dec 23;18(4):460–5.

11. Epidemiology of musculoskeletal tumors in Sardjito hospital Yogyakarta Indonesia [Internet]. Edorium Journals Pvt. Ltd.; 2020. Available from: http://dx.doi.org/10.5348/100005m05rm2018oa

12. Kamal AF, Widyawarman H, Husodo K, Hutagalung EU, Rajabto W. Clinical outcome and survival of osteosarcoma patients in Cipto Mangunkusumo Hospital: Limb salvage surgery versus amputation. Acta Med Indones. 2016 July;48(3):175–83.

13. Mahyudin F, Edward M, Basuki MH, Bari YA, Suwandani Y. Osteosarcoma has not become attention to society profile of osteosarcoma patients at Dr. Soetomo General Hospital Surabaya “a retrospective study.” (JOINTS) Journal Orthopaedi and Traumatology Surabaya. 2019 Dec 6;7(1):20.

14. Siregar Y, Nasution H, Lubis B. Clinical outcomes of osteosarcoma in H. Adam Malik General Hospital Medan: A retrospective study. Asian Pac J Cancer Prev. 2021;22(8):2491–7.

15. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 1994 June 1;54(11):3042–8.

16. Velletri T, Xie N, Wang Y, Huang Y, Yang Q, Chen X, et al. P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development. Cell Death Dis. 2016 Jan 21;7(1):e2015.

17. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014 Nov;14(11):722–35.

18. Broadhead ML, Clark JCM, Myers DE, Dass CR, Choong PFM. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011 Apr 13;2011:959248.

19. de Azevedo JWV, de Medeiros Fernandes TAA, Fernandes JV Jr, de Azevedo JCV, Lanza DCF, Bezerra CM, et al. Biology and pathogenesis of human osteosarcoma. Oncol Lett. 2020 Feb;19(2):1099–116.

20. Zheng Y, Wang G, Chen R, Hua Y, Cai Z. Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications. Stem Cell Res Ther. 2018 Jan 31;9(1):22.

21. Sun Z, Wang S, Zhao RC. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 2014 Feb 6;7(1):14.

22. Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. Indian J Orthop. 2014 May;48(3):238–46.

23. Chui MH, Kandel RA, Wong M, Griffin AM, Bell RS, Blackstein ME, et al. Histopathologic features of prognostic significance in high-grade osteosarcoma. Arch Pathol Lab Med. 2016 Nov;140(11):1231–42.

24. Rozeman LB, Cleton-Jansen AM, Hogendoorn PCW. Pathology of primary malignant bone and cartilage tumours. Int Orthop. 2006 Dec;30(6):437–44.

25. Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther. 2016 Dec;3(2):221–43.

26. George A, Grimer R. Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier? Ann R Coll Surg Engl. 2012 May;94(4):261–6.

27. Kumar VS, Barwar N, Khan SA. Surface osteosarcomas: Diagnosis, treatment and outcome. Indian J Orthop. 2014 May;48(3):255–61.

28. Nascimento D, Suchard G, Hatem M, de Abreu A. The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions. Insights Imaging. 2014 Aug;5(4):419–40.

29. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jürgens H, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol. 2001 Apr;12(4):479–86.

30. Soares do Brito J, Santos R, Sarmento M, Fernandes P, Portela J. Chemotherapy regimens for non-metastatic conventional appendicular osteosarcoma: A literature review based on the outcomes. Curr Oncol. 2023 June 27;30(7):6148–65.

31. Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J. 2018 Apr 9;4:12.

32. Jaffe N, Frei E 3rd, Traggis D, Watts H. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977 Jan;39(1):45–50.

33. Xu J, Xie L, Guo W. Neoadjuvant chemotherapy followed by delayed surgery: Is it necessary for all patients with nonmetastatic high-grade pelvic osteosarcoma? Clin Orthop Relat Res. 2018 Nov;476(11):2177–86.

34. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018 Jan;18(1):39–50.

35. Breden S, Beischl S, Hinterwimmer F, Consalvo S, Knebel C, von Eisenhart-Rothe R, et al. Surgical margin analysis in osteosarcoma: Impact on survival and local control. Cancers (Basel). 2025 Aug 6;17(15):2581.

36. Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol. 2010 July;121(1–2):297–300.

37. Cashman KD, Kiely M. Tackling inadequate vitamin D intakes within the population: fortification of dairy products with vitamin D may not be enough. Endocrine. 2016 Jan;51(1):38–46.

38. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000 Sept;72(3):690–3.

39. Kurucu N, Şahin G, Sarı N, Ceylaner S, İlhan İE. Association of vitamin D receptor gene polymorphisms with osteosarcoma risk and prognosis. J Bone Oncol. 2019 Feb;14(100208):100208.

40. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982 Jan 9;1(8263):74–6.

41. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 Aug;67(2):373–8.

42. Fu Y, Lan T, Cai H, Lu A, Yu W. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma. Medicine (Baltimore). 2018 May;97(19):e0741.

43. Liberti MV, Locasale JW. The Warburg Effect: How does it benefit cancer cells? Trends Biochem Sci. 2016 Mar;41(3):211–8.